Your browser doesn't support javascript.
Variant Analysis of SARS-CoV-2 Genomes from Belgian Military Personnel Engaged in Overseas Missions and Operations.
Pirnay, Jean-Paul; Selhorst, Philippe; Hong, Samuel L; Cochez, Christel; Potter, Barney; Maes, Piet; Petrillo, Mauro; Dudas, Gytis; Claes, Vincent; Van der Beken, Yolien; Verbeken, Gilbert; Degueldre, Julie; Dellicour, Simon; Cuypers, Lize; T'Sas, France; Van den Eede, Guy; Verhasselt, Bruno; Weuts, Wouter; Smets, Cedric; Mertens, Jan; Geeraerts, Philippe; Ariën, Kevin K; André, Emmanuel; Neirinckx, Pierre; Soentjens, Patrick; Baele, Guy.
  • Pirnay JP; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Selhorst P; Unit of Virology and Outbreak Research Team, Department of Biomedical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
  • Hong SL; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
  • Cochez C; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Potter B; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
  • Maes P; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
  • Petrillo M; European Commission, Directorate-General Joint Research Centre (JRC), 21027 Ispra, Italy.
  • Dudas G; Gothenburg Global Biodiversity Centre, 413 19 Gothenburg, Sweden.
  • Claes V; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, 08410 Vilnius, Lithuania.
  • Van der Beken Y; Clinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Verbeken G; Clinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Degueldre J; Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Dellicour S; Clinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Cuypers L; Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, 3000 Leuven, Belgium.
  • T'Sas F; Spatial Epidemiology Lab (SpELL), Université Libre de Bruxelles, 1050 Bruxelles, Belgium.
  • Van den Eede G; Department of Laboratory Medicine, UZ Leuven Hospital, 3000 Leuven, Belgium.
  • Verhasselt B; Clinical Laboratory, Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Weuts W; European Commission, Directorate-General Joint Research Centre (JRC), 1050 Brussels, Belgium.
  • Smets C; Department of Diagnostic Sciences, Ghent University Hospital, Ghent University, 9000 Ghent, Belgium.
  • Mertens J; Queen Astrid Military Hospital, 1120 Brussels, Belgium.
  • Geeraerts P; 14th Medical Battalion, 1800 Peutie, Belgium.
  • Ariën KK; Medical Component, Ministry of Defense, 1140 Brussels, Belgium.
  • André E; Medical Component, Ministry of Defense, 1140 Brussels, Belgium.
  • Neirinckx P; Unit of Virology, Department of Biomedical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
  • Soentjens P; Department of Biomedical Sciences, University of Antwerp, 2610 Antwerp, Belgium.
  • Baele G; Department of Laboratory Medicine, UZ Leuven Hospital, 3000 Leuven, Belgium.
Viruses ; 13(7)2021 07 13.
Article in English | MEDLINE | ID: covidwho-1314760
ABSTRACT
More than a year after the first identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the causative agent of the 2019 coronavirus disease (COVID-19) in China, the emergence and spread of genomic variants of this virus through travel raise concerns regarding the introduction of lineages in previously unaffected regions, requiring adequate containment strategies. Concomitantly, such introductions fuel worries about a possible increase in transmissibility and disease severity, as well as a possible decrease in vaccine efficacy. Military personnel are frequently deployed on missions around the world. As part of a COVID-19 risk mitigation strategy, Belgian Armed Forces that engaged in missions and operations abroad were screened (7683 RT-qPCR tests), pre- and post-mission, for the presence of SARS-CoV-2, including the identification of viral lineages. Nine distinct viral genotypes were identified in soldiers returning from operations in Niger, the Democratic Republic of the Congo, Afghanistan, and Mali. The SARS-CoV-2 variants belonged to major clades 19B, 20A, and 20B (Nextstrain nomenclature), and included "variant of interest" B.1.525, "variant under monitoring" A.27, as well as lineages B.1.214, B.1, B.1.1.254, and A (pangolin nomenclature), some of which are internationally monitored due to the specific mutations they harbor. Through contact tracing and phylogenetic analysis, we show that isolation and testing policies implemented by the Belgian military command appear to have been successful in containing the influx and transmission of these distinct SARS-CoV-2 variants into military and civilian populations.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Military Personnel Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa / Asia / Europa Language: English Year: 2021 Document Type: Article Affiliation country: V13071359

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Military Personnel Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa / Asia / Europa Language: English Year: 2021 Document Type: Article Affiliation country: V13071359